Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-26
2011-04-26
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C514S825000, C424S154100
Reexamination Certificate
active
07931901
ABSTRACT:
Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described. Also, the use of said polynucleotide, vector, protein, peptide, polypeptide, or antibody for the preparation of pharmaceutical compositions for use in organ transplantation, for the treatment of autoimmune, allergic or infectious diseases, or for treatment of tumors is provided. Furthermore, methods for modulating (antigen-specific) T cell unresponsiveness inducing maintaining or reversing T cell unresponsiveness by inhibiting or stimulating an (unresponsive) T cell through the novel TIRC7 membrane protein are encompassed herein.
REFERENCES:
patent: 5747034 (1998-05-01), de Boer et al.
patent: 6777537 (2004-08-01), Stashenko et al.
patent: 2005/0220789 (2005-10-01), Utku et al.
patent: 2005/0271659 (2005-12-01), Utku et al.
patent: WO/94/23033 (1994-10-01), None
patent: WO 98/03651 (1998-01-01), None
Webb et al., Eur J Immunol. Oct. 1996;26(10):2320-8.
Mavilia et al., Am J Pathol. Dec. 1997;151(6):1751-8.
Horwitz et al., Arthritis Rheum. May 1998;41(5):838-44.
Perrin et al., J Immunol. Feb. 1, 1995;154(3):1481-90.
Garcia-Cozar et al., Clin Exp Immunol. Apr. 1996;104(1):72-9.
Lenschown et al., J Exp Med. Mar. 1, 1995;181(3):1145-55.
Larger et al., Diabetes Care. Jul. 2004;27(7):1842-3.
O'Garra et al., Current Opinion in Immunology 1997, 9:872-883.
Kelso et al., Immunology Today, 374, vol. 16, No. 8, (1995).
Database Embl [Online] ID No. HS1196311, AC No. AA293678, Apr. 22, 1997 Hillier L et al:Homo sapienscDNA clone similar to specific 116-kDa vacuolar proton pump subunit.
Database Embl [Online] AC No. A1088498, Aug. 19, 1998 NCI-CGAP:Homo sapienscDNA clone similar to specific 116-kDa vacuolar proton pump subunit.
Heinemann, T. et al., (1999) “Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation”,Genomics57:398-406, XP000999606.
Amac, N. et al., (1994) “Identification of a New Human (H+)—ATPase Proton Pump Homology Differentially Expressed in Alloactivated Lymphocytes”, Poster Abstract for the American Society of Nephrology 27thAnnual Meeting, Oct. 26-29, 1994,J. Am. Soc. Nephrology5(3): 740.
Amac et al., (1996) “Characterization of a Novel Human Gene (C7) Associated with Early Lymphocyte Activation”, Poster Abstract for the Fifteen Annual Meeting of the American Society of Transplant Physicians, May 27-30, 1996, No. P-6, p. 174.
Utku, Nalan et al., (1997) “Identification of T Cell Immune Response cDNA (TIRC7) in Alloactivated Human Lymphocytes”, Fifth Basic Sciences Symposium of the Transplantation Society, Program & Poster Abstracts, Sep. 6-11, 1997.
Utku, Nalan et al., (1997) “Characterization of a Novel T Cell Immune Response cDNA (TIRC7) Associated with Early Lymphocyte Activation”,Fourth International Symposium on Clinical Immunology, Jun. 19-22, 1997 (Abstract).
Utku, Nalan et al., (1997) “Characterization of a Novel T-Cell Immune Response cDNA (TIRC7) Associated with Early Lymphocyte Activation”, XIIIth Spring Meeting of the Deutsche Gasellschaft für Immunologie, Mar. 6-8, 1997 (Abstract).
Utku, Nalan et al., (1998) “Antibodies to a Novel T Cell Antigen, TIRC7, Block Selectively TYP 1 But Not TYP 2 T-Cell Activation and Prolongs Allograft Survival”, Poster Abstract for the 17thAnnual Scientific Meeting, Jan. 9, 1998 (abstract).
Chuntharapai, Anan et al., (1997) “Generation of Monoclonal Antibodies to Chemokine Receptors”,Methods in Enzymology, vol. 288, pp. 15-27.
Kumamoto, Yusuke et al., (2004) “Monoclonal Antibody Specific for TIRC7 Induces Donor-specific Anergy and Prevents Rejection of Cardiac Allografts in Mice”,American Journal of Transplantation, vol. 4, pp. 505-514.
Utku, Nalan et al., (2004) “TIRC7 Deficiency Causes In Vitro and In Vivo Augmentation of T and B Cell Activation and Cytokine Response”,The Journal of Immunology, vol. 173, pp. 2342-2352.
Utku, N et al. (1998) “Prevention of Acute Allograft Rejection by Antibody Targeting of TIRC7 a Novel T Cell Membrane Protein”,Immunity, vol. 9, pp. 509-518.
Sato S.B. and Toyama S. (1994) Interference With the Endosomal Acidification by a Monoclonal Antibody Directed Toward the 116 (100)-kD Subunit of the Vacuolar Type Proton Pump,The Journal of Cell Biology, vol. 127, No. 1, pp. 39-53.
Owens et al., (1994) “The genetic Engineering ofMonoclonal Antibodies”,Journal of Immunological Methods, 168: 149-165.
Harlow et al., (1998) “Antibodies: A Laboratory Manual”,Cold Spring Harbor Laboratory, pp. content vi, 321-322.
Utku, N. et al., (1998) “Antibodies to a Novel T Xell Antigen, TIRC7, block selectively typ 1 but not typ 2 T-Cell Activation and Prolongs Allograft Survival”,Transplantation, 1(5) Supplement (abstract).
Li, Yi-Peng et al., (1996) “Molecular cloning and characterization of . . .”Biochemical and Biophysical Research Communications, 218 (3) :813-821.
Lee, C. et al., (1990) “Cloning of a cDNA for a T Cell Produced Molecule with a putative . . .”Molecular Immunology27(11): 1137-1144.
Campbell, A., (1985) “Monoclonal Antibody Technology”,Elsevier Science PublishersB.V., 2ndEdition, pp. 29.
Gavilondo and Larrick, (2000) “Antibody Engineering at the Millenium”,Biotechniques, 29:128-145.
Utku, N. et al. (1997) “Identification of T-cell Immune Response cDNA (TIRC7) in Alloactivated Human Lymphocytes,”Congress of Molecular Medicine, Berlin, May 3-5, 1997 (abstract).
Verhoef et al., (1998) “Mutual Antagonism of Rheumatoid Arthritis and Hay Fever; a Role for Type 1/Type 2 T Cell Balance”, Ann Rheum Dis 1998 57: 275-280.
Rabinovitch and Suarez-Pinzon, (1998) “Cytokines and Their Roles in Pancreatic Islet β-Cell Destruction and Insulin-Dependent Diabetes Mellitus” Biochemical Pharmacology, vol. 55, pp. 1139-1149.
Correale et al., (1995) “Patterns of Cytokine Secretion by Autoreactive Proteolipid Protein-Specific T Cell Clones During the Course of Multiple Sclerosis” J. Immunol. 1995; 154; 2959-2968.
Haas et al., (1998) “IFN-γ Receptor Deletion Prevents Autoantibody Production and Glomerulonephritis in Lupus-Prone(NZB x NZW)F1Mice” J. Immunol. 1998; 160; 3713-3718.
Mariani et al., (2003) “Silencing Autoimmunity: Manipulating Interferon in Systemic Lupus Erythematosus” Medscape Molecular Medicine. 2003;5(1).
Kirk et al., (1997) “CTLA4-Ig and Anti-CD40 Ligand Prevent Renal Allograft Rejection in Primates” Pro. Natl. Acad. Sci USA, vol. 97, pp. 8789-8794, Aug. 1997.
Clinical Trial Study No. NCT00534313, “Safety and Efficacy of Abatacept Versus Placebo in Subjects With Psoriatic Arthritis” printed from clincaltrials.gov.
Clinical Trial Study No. NCT01012492, “Safety and Tolerability of Abatacept-Based Immunosuppression for Prevention of Acute Graft Versus Host Disease(aGVHD)During Transplant” printed from clincaltrials.gov.
Schlaak et al., (1994) “T Cells Involved in Psoriasis
Gullans Steven R.
Milford Edgar L.
Utku Nalan
Cooper & Dunham LLP
Skelding Zachary
The Brigham and Women's Hospital, Inc.
Utku Nalan
White John P.
LandOfFree
T-cell membrane protein (TIRC7), peptides and antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T-cell membrane protein (TIRC7), peptides and antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T-cell membrane protein (TIRC7), peptides and antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654969